387 related articles for article (PubMed ID: 16173012)
41. Visualization of enteroviral replication in myocardial tissue by ultrastructural in situ hybridization: identification of target cells and cytopathic effects.
Klingel K; Rieger P; Mall G; Selinka HC; Huber M; Kandolf R
Lab Invest; 1998 Oct; 78(10):1227-37. PubMed ID: 9800948
[TBL] [Abstract][Full Text] [Related]
42. Viral myocarditis: identification of five differentially expressed genes in coxsackievirus B3-infected mouse heart.
Yang D; Yu J; Luo Z; Carthy CM; Wilson JE; Liu Z; McManus BM
Circ Res; 1999 Apr; 84(6):704-12. PubMed ID: 10189358
[TBL] [Abstract][Full Text] [Related]
43. CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis.
Yuan J; Liu Z; Lim T; Zhang H; He J; Walker E; Shier C; Wang Y; Su Y; Sall A; McManus B; Yang D
Circ Res; 2009 Mar; 104(5):628-38. PubMed ID: 19168435
[TBL] [Abstract][Full Text] [Related]
44. Genomic determinants of cardiovirulence in coxsackievirus B3 clinical isolates: localization to the 5' nontranslated region.
Dunn JJ; Chapman NM; Tracy S; Romero JR
J Virol; 2000 May; 74(10):4787-94. PubMed ID: 10775617
[TBL] [Abstract][Full Text] [Related]
45. Cooperative and specific binding of Vif to the 5' region of HIV-1 genomic RNA.
Henriet S; Richer D; Bernacchi S; Decroly E; Vigne R; Ehresmann B; Ehresmann C; Paillart JC; Marquet R
J Mol Biol; 2005 Nov; 354(1):55-72. PubMed ID: 16236319
[TBL] [Abstract][Full Text] [Related]
46. La autoantigen is required for the internal ribosome entry site-mediated translation of Coxsackievirus B3 RNA.
Ray PS; Das S
Nucleic Acids Res; 2002 Oct; 30(20):4500-8. PubMed ID: 12384597
[TBL] [Abstract][Full Text] [Related]
47. Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease.
Henke A; Jarasch N; Martin U; Wegert J; Wildner A; Zell R; Wutzler P
Int J Med Microbiol; 2008 Jan; 298(1-2):127-34. PubMed ID: 17897883
[TBL] [Abstract][Full Text] [Related]
48. Mutations in the 5' NTR and the Non-Structural Protein 3A of the Coxsackievirus B3 Selectively Attenuate Myocarditogenicity.
Massilamany C; Gangaplara A; Basavalingappa RH; Rajasekaran RA; Vu H; Riethoven JJ; Steffen D; Pattnaik AK; Reddy J
PLoS One; 2015; 10(6):e0131052. PubMed ID: 26098885
[TBL] [Abstract][Full Text] [Related]
49. Distribution of viral RNA in mouse tissues during acute phase of coxsackievirus B5 infection.
Moon MS; Joo CH; Hwang IS; Ye JS; Jun EJ; Lee HS; Kim D; Lee MJ; Lee H; Kim YK
Intervirology; 2005; 48(2-3):153-60. PubMed ID: 15812189
[TBL] [Abstract][Full Text] [Related]
50. The apoptotic capability of coxsackievirus B3 is influenced by the efficient interaction between the capsid protein VP2 and the proapoptotic host protein Siva.
Henke A; Nestler M; Strunze S; Saluz HP; Hortschansky P; Menzel B; Martin U; Zell R; Stelzner A; Munder T
Virology; 2001 Oct; 289(1):15-22. PubMed ID: 11601913
[TBL] [Abstract][Full Text] [Related]
51. Targeting 2A protease by RNA interference attenuates coxsackieviral cytopathogenicity and promotes survival in highly susceptible mice.
Merl S; Michaelis C; Jaschke B; Vorpahl M; Seidl S; Wessely R
Circulation; 2005 Apr; 111(13):1583-92. PubMed ID: 15795330
[TBL] [Abstract][Full Text] [Related]
52. A phosphorothioate antisense oligodeoxynucleotide specifically inhibits coxsackievirus B3 replication in cardiomyocytes and mouse hearts.
Yuan J; Cheung PK; Zhang H; Chau D; Yanagawa B; Cheung C; Luo H; Wang Y; Suarez A; McManus BM; Yang D
Lab Invest; 2004 Jun; 84(6):703-14. PubMed ID: 15094712
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of coxsackievirus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand.
Yuan J; Cheung PK; Zhang HM; Chau D; Yang D
J Virol; 2005 Feb; 79(4):2151-9. PubMed ID: 15681418
[TBL] [Abstract][Full Text] [Related]
54. 5'-Terminal deletions occur in coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA.
Kim KS; Tracy S; Tapprich W; Bailey J; Lee CK; Kim K; Barry WH; Chapman NM
J Virol; 2005 Jun; 79(11):7024-41. PubMed ID: 15890942
[TBL] [Abstract][Full Text] [Related]
55. Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1.
Schmidtke M; Selinka HC; Heim A; Jahn B; Tonew M; Kandolf R; Stelzner A; Zell R
Virology; 2000 Sep; 275(1):77-88. PubMed ID: 11017789
[TBL] [Abstract][Full Text] [Related]
56. Experimental SSM-CVB3 infection in macaques.
Han T; He W; Song D; Zhao K; Wu C; Gao F; Lu H; Gai X; Wang X; Li F; Ji C; Lin X
Exp Mol Pathol; 2012 Feb; 92(1):131-9. PubMed ID: 22079478
[TBL] [Abstract][Full Text] [Related]
57. Secondary heterotypic versus homotypic infection by Coxsackie B group viruses: impact on early and late histopathological lesions and virus genome prominence.
Yu JZ; Wilson JE; Wood SM; Kandolf R; Klingel K; Yang D; McManus BM
Cardiovasc Pathol; 1999; 8(2):93-102. PubMed ID: 10724506
[TBL] [Abstract][Full Text] [Related]
58. Antibody-dependent enhancement of coxsackievirus B3 infection of primary CD19+ B lymphocytes.
Jarasch-Althof N; Wiesener N; Schmidtke M; Wutzler P; Henke A
Viral Immunol; 2010 Aug; 23(4):369-76. PubMed ID: 20712481
[TBL] [Abstract][Full Text] [Related]
59. Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling: implications for mortality and early viral replication.
Wessely R; Klingel K; Knowlton KU; Kandolf R
Circulation; 2001 Feb; 103(5):756-61. PubMed ID: 11156890
[TBL] [Abstract][Full Text] [Related]
60. Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis.
Lim BK; Choi JH; Nam JH; Gil CO; Shin JO; Yun SH; Kim DK; Jeon ES
Cardiovasc Res; 2006 Aug; 71(3):517-26. PubMed ID: 16806133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
